Published in Arch Neurol on March 01, 1998
APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol (2010) 6.17
The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex (2008) 5.36
Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol (2009) 4.71
Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol (2009) 4.55
Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging (2009) 4.36
Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET). Proc Natl Acad Sci U S A (2001) 3.86
Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol (2012) 3.77
Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol (2014) 3.75
Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. Arch Neurol (2009) 3.60
Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. Lancet Neurol (2013) 3.46
Longitudinal study of the transition from healthy aging to Alzheimer disease. Arch Neurol (2009) 3.35
Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging (2005) 3.32
HDDD2 is a familial frontotemporal lobar degeneration with ubiquitin-positive, tau-negative inclusions caused by a missense mutation in the signal peptide of progranulin. Ann Neurol (2006) 3.00
Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship. J Neuropathol Exp Neurol (2009) 2.87
Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. EMBO Mol Med (2009) 2.87
Clinicopathologic correlations in a large Alzheimer disease center autopsy cohort: neuritic plaques and neurofibrillary tangles "do count" when staging disease severity. J Neuropathol Exp Neurol (2007) 2.65
Alzheimer disease and cognitive reserve: variation of education effect with carbon 11-labeled Pittsburgh Compound B uptake. Arch Neurol (2008) 2.62
Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology (2011) 2.61
Variants in the ATP-binding cassette transporter (ABCA7), apolipoprotein E ϵ4,and the risk of late-onset Alzheimer disease in African Americans. JAMA (2013) 2.58
Cardiorespiratory fitness and brain atrophy in early Alzheimer disease. Neurology (2008) 2.56
Modeling the association between 43 different clinical and pathological variables and the severity of cognitive impairment in a large autopsy cohort of elderly persons. Brain Pathol (2008) 2.44
Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition. Proc Natl Acad Sci U S A (2008) 2.44
Large deformation diffeomorphism and momentum based hippocampal shape discrimination in dementia of the Alzheimer type. IEEE Trans Med Imaging (2007) 2.24
Regional white matter volume differences in nondemented aging and Alzheimer's disease. Neuroimage (2008) 2.23
Abnormalities of hippocampal surface structure in very mild dementia of the Alzheimer type. Neuroimage (2005) 2.20
Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology (2013) 2.19
Seeded growth of beta-amyloid fibrils from Alzheimer's brain-derived fibrils produces a distinct fibril structure. Proc Natl Acad Sci U S A (2009) 2.15
Differential effects of aging and Alzheimer's disease on medial temporal lobe cortical thickness and surface area. Neurobiol Aging (2007) 2.09
A scan of chromosome 10 identifies a novel locus showing strong association with late-onset Alzheimer disease. Am J Hum Genet (2005) 2.04
Cardiorespiratory fitness and preserved medial temporal lobe volume in Alzheimer disease. Alzheimer Dis Assoc Disord (2009) 1.99
Distinct pools of beta-amyloid in Alzheimer disease-affected brain: a clinicopathologic study. Arch Neurol (2008) 1.92
Increased metabolic vulnerability in early-onset Alzheimer's disease is not related to amyloid burden. Brain (2010) 1.86
Improving CSF biomarker accuracy in predicting prevalent and incident Alzheimer disease. Neurology (2011) 1.84
Relationship of dementia screening tests with biomarkers of Alzheimer's disease. Brain (2010) 1.80
Blood pressure and brain injury in older adults: findings from a community-based autopsy study. J Am Geriatr Soc (2009) 1.76
Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age. JAMA Neurol (2015) 1.70
Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. Arch Neurol (2009) 1.68
Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo. Behav Neurol (2009) 1.67
Cognitive profiles in dementia: Alzheimer disease vs healthy brain aging. Neurology (2008) 1.62
Cerebrospinal fluid Aβ42, phosphorylated Tau181, and resting-state functional connectivity. JAMA Neurol (2013) 1.60
SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease. PLoS Genet (2010) 1.58
In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia. Neurology (2010) 1.58
Using mice to model Alzheimer's dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models. Front Genet (2014) 1.56
Amyloid mediates the association of apolipoprotein E e4 allele to cognitive function in older people. J Neurol Neurosurg Psychiatry (2005) 1.55
Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease. Ann Neurol (2011) 1.51
Comparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology. Arch Neurol (2011) 1.50
Plaque and tangle imaging and cognition in normal aging and Alzheimer's disease. Neurobiol Aging (2008) 1.49
Open access series of imaging studies: longitudinal MRI data in nondemented and demented older adults. J Cogn Neurosci (2010) 1.49
Reduced lean mass in early Alzheimer disease and its association with brain atrophy. Arch Neurol (2010) 1.47
Alzheimer disease pathology as a host response. J Neuropathol Exp Neurol (2008) 1.45
Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease. Sci Transl Med (2014) 1.45
Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer's disease. Hum Mol Genet (2012) 1.43
Impact of APOE on the healthy aging brain: a voxel-based MRI and DTI study. J Alzheimers Dis (2009) 1.40
The utility of intraindividual variability in selective attention tasks as an early marker for Alzheimer's disease. Neuropsychology (2009) 1.37
Predicting the location of entorhinal cortex from MRI. Neuroimage (2009) 1.35
C9orf72 hexanucleotide repeat expansions in clinical Alzheimer disease. JAMA Neurol (2013) 1.34
Association and expression analyses with single-nucleotide polymorphisms in TOMM40 in Alzheimer disease. Arch Neurol (2011) 1.34
Preclinical syndromes predict dementia: the Sydney older persons study. J Neurol Neurosurg Psychiatry (2001) 1.30
Molecular characterization of novel progranulin (GRN) mutations in frontotemporal dementia. Hum Mutat (2008) 1.30
Revised criteria for mild cognitive impairment may compromise the diagnosis of Alzheimer disease dementia. Arch Neurol (2012) 1.29
Atrophy of the cholinergic Basal forebrain over the adult age range and in early stages of Alzheimer's disease. Biol Psychiatry (2011) 1.29
Effects of healthy aging and early stage dementia of the Alzheimer's type on components of response time distributions in three attention tasks. Neuropsychology (2010) 1.27
The oxidative stress metabolite 4-hydroxynonenal promotes Alzheimer protofibril formation. Biochemistry (2007) 1.25
Effects of stress and stress hormones on amyloid-beta protein and plaque deposition. J Alzheimers Dis (2009) 1.20
Cognition, glucose metabolism and amyloid burden in Alzheimer's disease. Neurobiol Aging (2010) 1.19
Memory efficiency and the strategic control of attention at encoding: impairments of value-directed remembering in Alzheimer's disease. Neuropsychology (2009) 1.19
Potential mechanisms contributing to sulfatide depletion at the earliest clinically recognizable stage of Alzheimer's disease: a tale of shotgun lipidomics. J Neurochem (2007) 1.18
Toward a multifactorial model of Alzheimer disease. Neurobiol Aging (2012) 1.16
Labeled cortical mantle distance maps of the cingulate quantify differences between dementia of the Alzheimer type and healthy aging. Proc Natl Acad Sci U S A (2003) 1.16
Alzheimer disease identification using amyloid imaging and reserve variables: proof of concept. Neurology (2010) 1.15
Selective cell death of hyperploid neurons in Alzheimer's disease. Am J Pathol (2010) 1.15
Accelerating regional atrophy rates in the progression from normal aging to Alzheimer's disease. Eur Radiol (2009) 1.14
Predicting conversion to dementia of the Alzheimer's type in a healthy control sample: the power of errors in Stroop color naming. Psychol Aging (2010) 1.14
Reexamining Alzheimer's disease: evidence for a protective role for amyloid-beta protein precursor and amyloid-beta. J Alzheimers Dis (2009) 1.13
Predictors of mortality in patients with Alzheimer's disease living in nursing homes. J Neurol Neurosurg Psychiatry (1999) 1.13
CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease. Neurology (2012) 1.13
Alterations of the sphingolipid pathway in Alzheimer's disease: new biomarkers and treatment targets? Neuromolecular Med (2010) 1.12
Progression of Alzheimer's disease as measured by Clinical Dementia Rating Sum of Boxes scores. Alzheimers Dement (2012) 1.12
Physical activity attenuates age-related biomarker alterations in preclinical AD. Neurology (2014) 1.10
7,8-dihydroxyflavone prevents synaptic loss and memory deficits in a mouse model of Alzheimer's disease. Neuropsychopharmacology (2013) 1.09
Resting bold fMRI differentiates dementia with Lewy bodies vs Alzheimer disease. Neurology (2011) 1.09
Trajectories of cognitive decline in Alzheimer's disease. Int Psychogeriatr (2009) 1.06
Stability of the Clinical Dementia Rating, 1979-2007. Arch Neurol (2009) 1.05
The PSEN1, p.E318G variant increases the risk of Alzheimer's disease in APOE-ε4 carriers. PLoS Genet (2013) 1.05
Cardiorespiratory fitness is associated with atrophy in Alzheimer's and aging over 2 years. Neurobiol Aging (2011) 1.05
The effects of aging and Alzheimer's disease on cerebral cortical anatomy: specificity and differential relationships with cognition. Neuroimage (2013) 1.05
APOE genotype and neuroimaging markers of Alzheimer's disease: systematic review and meta-analysis. J Neurol Neurosurg Psychiatry (2014) 1.04
Apolipoprotein E levels in cerebrospinal fluid and the effects of ABCA1 polymorphisms. Mol Neurodegener (2007) 1.04
Haplotype-based association analysis of the MAPT locus in late onset Alzheimer's disease. BMC Genet (2007) 1.02
Transient dynamics of Aβ contribute to toxicity in Alzheimer's disease. Cell Mol Life Sci (2014) 1.01
Added Diagnostic Value of (11)C-PiB-PET in Memory Clinic Patients with Uncertain Diagnosis. Dement Geriatr Cogn Dis Extra (2012) 1.01
Adult Changes in Thought study: dementia is an individually varying convergent syndrome with prevalent clinically silent diseases that may be modified by some commonly used therapeutics. Curr Alzheimer Res (2012) 1.01
The utility of Stroop task switching as a marker for early-stage Alzheimer's disease. Psychol Aging (2010) 1.01
Argyrophilic grain disease differs from other tauopathies by lacking tau acetylation. Acta Neuropathol (2013) 1.00
Rs5848 variant influences GRN mRNA levels in brain and peripheral mononuclear cells in patients with Alzheimer's disease. J Alzheimers Dis (2009) 1.00
Fully-automated, multi-stage hippocampus mapping in very mild Alzheimer disease. Hippocampus (2009) 0.99
Longitudinal measures of cholinergic forebrain atrophy in the transition from healthy aging to Alzheimer's disease. Neurobiol Aging (2012) 0.99
Diabetes is associated with cerebrovascular but not Alzheimer's disease neuropathology. Alzheimers Dement (2016) 0.99
Suggestive synergy between genetic variants in TF and HFE as risk factors for Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet (2010) 0.98
Stabilization of neurotoxic soluble beta-sheet-rich conformations of the Alzheimer's disease amyloid-beta peptide. Biophys J (2007) 0.98
Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science (1993) 33.32
Current concepts in mild cognitive impairment. Arch Neurol (2001) 18.09
Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature (1998) 15.24
Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A (1993) 15.04
Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology (1996) 12.33
[11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology (2006) 12.10
The organization of networks within the orbital and medial prefrontal cortex of rats, monkeys and humans. Cereb Cortex (2000) 11.57
Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol (1999) 10.45
Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet (2013) 9.46
Subgenual prefrontal cortex abnormalities in mood disorders. Nature (1997) 9.36
Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol (1987) 9.10
Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol (2001) 8.88
Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci (1996) 7.19
Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet (1994) 7.07
Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood (1998) 6.81
Patterns of brain activation in people at risk for Alzheimer's disease. N Engl J Med (2000) 6.72
Limbic connections of the orbital and medial prefrontal cortex in macaque monkeys. J Comp Neurol (1995) 6.37
Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci U S A (1993) 5.68
Strategies for reducing coronary heart disease and desirable limits for blood lipid concentrations: guidelines of the British Hyperlipidaemia Association. Br Med J (Clin Res Ed) (1987) 5.01
Inhibition of Trypanosoma brucei gene expression by RNA interference using an integratable vector with opposing T7 promoters. J Biol Chem (2000) 4.96
Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci U S A (1993) 4.86
Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A (2000) 4.85
Cancer linked to Alzheimer disease but not vascular dementia. Neurology (2009) 4.83
The Drosophila clock gene double-time encodes a protein closely related to human casein kinase Iepsilon. Cell (1998) 4.59
Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia (2011) 4.28
Neurofibrillary tangles of Alzheimer disease share antigenic determinants with the axonal microtubule-associated protein tau (tau) Proc Natl Acad Sci U S A (1986) 4.26
Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci U S A (1998) 4.16
Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science (1998) 4.07
Complete genomic screen in late-onset familial Alzheimer disease. Evidence for a new locus on chromosome 12. JAMA (1997) 4.00
Complications of gamma knife surgery for Parkinson disease. Arch Neurol (2001) 3.97
Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J (2006) 3.92
A functional anatomical study of unipolar depression. J Neurosci (1992) 3.85
Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. Arch Neurol (2001) 3.80
Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord (1997) 3.77
Hippocampal morphometry in schizophrenia by high dimensional brain mapping. Proc Natl Acad Sci U S A (1998) 3.72
The AD8: a brief informant interview to detect dementia. Neurology (2005) 3.65
Amygdalo-cortical projections in the monkey (Macaca fascicularis). J Comp Neurol (1984) 3.63
Normative estimates of cross-sectional and longitudinal brain volume decline in aging and AD. Neurology (2005) 3.55
Clinical dementia rating training and reliability in multicenter studies: the Alzheimer's Disease Cooperative Study experience. Neurology (1997) 3.53
Assessing family sharing of diabetes responsibilities. J Pediatr Psychol (1990) 3.43
A novel neurological phenotype in mice lacking mitochondrial manganese superoxide dismutase. Nat Genet (1998) 3.41
Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. J Mol Neurosci (2001) 3.35
Validation of the Delirium Rating Scale-revised-98: comparison with the delirium rating scale and the cognitive test for delirium. J Neuropsychiatry Clin Neurosci (2001) 3.35
Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N Engl J Med (1989) 3.32
Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. Neurology (2001) 3.30
Cerebral amyloid deposition and diffuse plaques in "normal" aging: Evidence for presymptomatic and very mild Alzheimer's disease. Neurology (1996) 3.29
Architectonic subdivision of the orbital and medial prefrontal cortex in the macaque monkey. J Comp Neurol (1994) 3.25
Loss of circadian behavioral rhythms and per RNA oscillations in the Drosophila mutant timeless. Science (1994) 3.24
Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. N Engl J Med (1998) 3.23
Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease: the CERAD experience, Part XV. Neurology (1996) 3.23
Connectional networks within the orbital and medial prefrontal cortex of macaque monkeys. J Comp Neurol (1996) 3.22
Preclinical detection of Alzheimer's disease: hippocampal shape and volume predict dementia onset in the elderly. Neuroimage (2005) 3.21
A longitudinal study of drivers with Alzheimer disease. Neurology (2008) 3.17
Functional brain imaging of young, nondemented, and demented older adults. J Cogn Neurosci (2000) 3.12
Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success? Int J Geriatr Psychiatry (2001) 3.09
Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol (2002) 3.02
A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology (2000) 2.99
The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease. Neurobiol Aging (1992) 2.97
Protection against Alzheimer's disease with apoE epsilon 2. Lancet (1994) 2.96
Difference in relapse rates of duodenal ulcer after healing with cimetidine or tripotassium dicitrato bismuthate. Lancet (1981) 2.95
Validity of clinical examination and mammography as screening tests for breast cancer. Lancet (1975) 2.95
Neuropathological and neuropsychological changes in "normal" aging: evidence for preclinical Alzheimer disease in cognitively normal individuals. J Neuropathol Exp Neurol (1998) 2.92
Prefrontal cortical projections to the hypothalamus in macaque monkeys. J Comp Neurol (1998) 2.91
Sensory and premotor connections of the orbital and medial prefrontal cortex of macaque monkeys. J Comp Neurol (1995) 2.85
Prefrontal cortical projections to longitudinal columns in the midbrain periaqueductal gray in macaque monkeys. J Comp Neurol (1998) 2.85
Normal brain in human newborns: apparent diffusion coefficient and diffusion anisotropy measured by using diffusion tensor MR imaging. Radiology (1998) 2.81
Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation. JAMA (1997) 2.81
American Academy of Neurology position statement on physician reporting of medical conditions that may affect driving competence. Neurology (2007) 2.79
Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. Biol Psychiatry (2001) 2.70
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part X. Neuropathology confirmation of the clinical diagnosis of Alzheimer's disease. Neurology (1995) 2.69
A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's disease. Pharmacogenomics J (2009) 2.66
Reliability and validity of DSM-IV axis V. Am J Psychiatry (2000) 2.59
Preparation and characterization of a plasma membrane fraction from isolated fat cells. J Cell Biol (1970) 2.53
Very mild Alzheimer's disease: informant-based clinical, psychometric, and pathologic distinction from normal aging. Neurology (1991) 2.53
Consortium to establish a registry for Alzheimer's disease (CERAD) clinical and neuropsychological assessment of Alzheimer's disease. Psychopharmacol Bull (1988) 2.50
Susceptibility locus for Alzheimer's disease on chromosome 10. Science (2000) 2.49
Genetic variation in the CHRNA5 gene affects mRNA levels and is associated with risk for alcohol dependence. Mol Psychiatry (2008) 2.49